[ News ] [ Our People ]
[Management Team ] [ Board of Directors ]
Board of Directors
Mohr, Ph.D., R.Psych., ICD.D
Chairman & Chief Executive Officer
Founder of MedGenesis Therapeutix Inc.
Dr. Mohr is the Chairman and CEO of MedGenesis Therapeutix Inc. which he
founded in 2006. Dr. Mohr, a Professor of Medicine and Psychology at the
University of Ottawa until 1997 has over 30 years of experience in experimental
therapeutics of CNS disorders. He is credited with over 150 publications, book
chapters and abstracts and has edited the Handbook of Clinical Trials: The
neurobehavioral approach. Dr. Mohr has chaired and/or served on several
regulatory advisory panels for the approval of new products for the treatment of
neurodegenerative disease and is the former Chairman and Chief Executive Officer
of CroMedica Global Inc. (which merged with PRA International in 2002 to form
one of the world's leading contract research organizations) and is the current
or past Chairman of several biotechnology companies. His most recent executive
position was with PRA International as Chief Scientific Officer. He also served
until recently as Chair of the Board of Governors of the University of Victoria.
Over the course of his career, Dr. Mohr has overseen and/or participated in more
than a dozen clinical development programs resulting in a number of approved drugs.
(Pat) K. Donnelly
Operating Partner and Board Director, ProPharma Group and Advarra
Board Director, Phase 5 LLC and Rediscovery Life Sciences
Mr. Donnelly, who has more than 35 years of experience, was most
recently Chairman and Chief Executive Officer of Aptiv Solutions, a
global pharmaceutical development services business he founded which was
sold to ICON (NASDAQ:ICLR) in May 2014. Prior to this, Pat served as
President, Chief Executive Officer, and was one of the founders of PRA
International (now PRA Health Sciences, NASDAQ:PRAH). He was
instrumental in building PRA over a period of twelve years from a small
regional contract research organization to a global leader in the
industry. Mr. Donnelly received his MBA. from Pennsylvania State
University in 1984 and received his BS from the University of Missouri
in 1980. Pat currently serves as an Operating Partner and as a board
director for Linden portfolio companies, ProPharma Group and Advarra.
Pat is also a board director at Phase 5 LLC, and Rediscovery Life
Christian Fibiger, Ph.D.
Independent Board Member
Associate Dean, Research, University of British Columbia
H. Christian Fibiger received his BSc in Chemistry and Psychology from the
University of Victoria and his PhD in Psychopharmacology from Princeton
University. He is currently Associate Dean, Research, in the Faculty of Medicine
at the University of British Columbia. Dr. Fibiger was formerly the Chief
Scientific Officer and Senior Vice President at Biovail Laboratories
International (2008 - 2010). From 2003 until 2007, he was Vice President and
Global Head of Neuroscience at Amgen. In this position he was responsible for
Amgen's worldwide Neuroscience discovery efforts ranging from early exploratory
research through clinical candidate selection. Prior to joining Amgen in 2003,
Dr. Fibiger served as Vice President of Neuroscience Discovery Research and
Clinical Investigation, and Lilly Research Laboratories in Europe at Eli Lilly
and Company. Dr. Fibiger previously served as Professor and Head of the Division
of Neurological Sciences and Chair of the University Graduate Program in
Neuroscience at the University of British Columbia. Professor Fibiger has made
numerous contributions to neuroscience research and, during his academic career,
was among the world's 100 most cited scientists in neuroscience. He has received
many honors for his research contributions, including the Clark Institute Prize
in Psychiatry, the Heinz Lehmann Award of the Canadian College of
Neuropsychopharmacology, the Killam Research Prize, the Gold Medal in Health
Sciences from the Science Council of British Columbia, and the Tanenbaum
Distinguished Scientist Award in Schizophrenia Research. He is a Fellow of the
American College of Neuropsychopharmacology. Professor Fibiger has served on the
editorial boards of major neuroscience journals and was co-editor of
Neuropsychopharmacology, the official publication of the American College of
Neuropsychopharmacology. He currently serves on the Board of several for profit
and nonprofit organizations.
Former President, CroMedica Global Inc.
Ken Newport is an entrepreneur and life sciences business executive. As a
graduate of the University of Waterloo and a Chartered Accountant, Mr. Newport
had early success in the financial services industry and served as a partner in
a Chartered Accounting firm. His focus changed to life sciences in the
mid-nineties with the formation of CroMedica Global Inc., a contract research
organization. As co-founder and President he witnessed CroMedica's growth to 600
employees within six years. By the time that CroMedica merged with PRA
International Inc. in 2002 CroMedica had annual revenues of over $40 million
with 13 offices in 9 countries. The combined company became one of the 5 largest
contract research organizations in the world with 2,600 employees. Mr. Newport
served as a Senior Vice President and Executive Committee member until 2005. Mr.
Newport was also a founding member of Global Biomedical Capital Corporation,
Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations.
He is now a corporate director and has earned the ICD.D designation. He serves
or has served on several corporate and not for profit Boards including his role
as Chairman of BioCanRx.